GlobeNewswire Inc | Jan 6, 2022 12:00PM EST

January 06, 2022

LYON, France, Jan. 06, 2022 (GLOBE NEWSWIRE) -- ADOCIA SA, a French socit anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 ADOC) a clinical stage biopharmaceutical company focused on diabetes treatments and other metabolic diseases with innovative formulations of peptides and proteins, announced today its financial calendar for 2022.

February 23, 2022: Publication of revenue for Q4 2021.April 19, 2022: Publication of 2021 financial statements.May 18, 2022: Publication of revenue for Q1 2022.August 24, 2022: Publication of revenue for Q2 2022.September 19, Publication of mid-year financial statements as of June 30,2022: 2022.October 25, 2022: Publication of revenue for Q3 2022.

In addition to regular meetings with the financial community, investors can also find updated information on the companys website (www.adocia.com). All corporate information on the company such as its financial statements, its corporate presentation and its status is available on the companys website, in the Investors section, Regulated Information.

About Adocia

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of therapeutic peptides and proteins for the treatment of diabetes and metabolic diseases. In the diabetes field, Adocias portfolio of injectable treatments is among the largest and most differentiated of the industry, featuring six clinical-stage products and several pre-clinical products.

Adocias clinical pipeline includes five novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and rapid acting insulin lispro (BioChaperone Combo) and two combinations of a prandial insulin with amylin analog pramlintide (M1Pram and BioChaperone LisPram). The clinical pipeline also includes an aqueous formulation of human glucagon (BioChaperone Glucagon) for the treatment of hypoglycemia.

Adocias preclinical pipeline includes bi-hormonal combinations for diabetes treatment: a combination of aspart rapid acting insulin analog and pramlintide (BioChaperone AsPram), a combination of insulin glargine with GLP-1 receptor agonist (BioChaperone Glargine Liraglutide). In addition, there are three multi-hormonal products for the treatment of obesity: a combination of glucagon and exenatide (BioChaperone GluExe), a combination of pramlintide and exenatide (PramExe) and a triple combination of pramlintide glucagon exenatide (BioChaperone PramGluExe).

Adocia's portfolio is based on three technology platforms: 1) The BioChaperone platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use; 2) A platform designed to improve cell therapy techniques using a hydrogel matrix; 3) A platform for the oral delivery of peptides.

Contact Adocia

Adocia MC Services AGGrard Soula Adocia Press Relations EuropeCEO Raimund Gabriel, Shaun Brown, Andreas Jungfercontactinvestisseurs@adocia.com adocia@mc-services.euPh: +33 4 72 610610 Ph: +49 89 210 228 0www.adocia.com

Disclaimer

This press release contains certain forward-looking statements concerningAdocia and its business. Such forward-looking statements are based onassumptions that Adocia considers as being reasonable. However, there can be noguarantee that the estimates contained in such forward-looking statements willbe achieved, as such estimates are subject to numerous risks including thosewhich are set forth in the ?Risk Factors? section of the universal registrationdocument that was filed with the French Autorit des marchs financiers onApril 20, 2021 (a copy of which is available at www.adocia.com), in particularuncertainties that are linked to research and development, future clinicaldata, analyses, and the evolution of the economiccontext, the financialmarkets and the markets in which Adocia operates.The forward-looking statements contained in this press release are also subjectto risks not yet known to Adocia or not considered as material by Adocia as ofthis day. The occurrence of all or part of such risks could cause that actualresults, financial conditions, performances, or achievements of Adocia bematerially different from those mentioned in the forward-looking statements.This press release and the information contained herein do not constitute anoffer to sell or the solicitation of an offer to buy Adocia?s shares in anyjurisdiction.